Angelman Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Video
• Funding
• Clinical Trials

Angelman Syndrome Video Assessment (ASVA) Source Material Study
Condition:   Angelman Syndrome Intervention:   Sponsors:   The Emmes Company, LLC;   Ionis Pharmaceuticals, Inc.;   Boston Children's Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials

Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype
Condition:   Angelman Syndrome Interventions:   Drug: 60 mg QD Alogabat;   Drug: 40 mg QD Alogabat;   Drug: 7 mg QD Alogabat;   Drug: Part 2 Adult Alogabat High Dose (aged 15-17);   Drug: Alogabat;   Drug: Aligabat Sponsor:   Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2022 Category: Research Source Type: clinical trials